Malignant endocrine neoplasm

Summary

Malignant endocrine neoplasm (MONDO:0021069) is a cancer (an umbrella term covering 16 Mondo subtypes) and 9 clinical trials. Top therapeutic interventions include gemcitabine, psilocybin, and mebufotenin. A subtype of endocrine gland neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 16 Mondo subtypes
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant endocrine neoplasm
Mondo ID	MONDO:0021069
MeSH	D004701
DOID	DOID:170
NCIT	C3575
UMLS	C0153658
MedGen	56319
Anatomy (UBERON)	UBERON:0002368
Is cancer (heuristic)	yes

Also known as: cancer of endocrine gland · endocrine cancer · endocrine gland cancer · endocrine neoplasm · endocrine neoplasm, malignant · Endocrine tumour · malignant endocrine gland neoplasm · malignant endocrine gland tumor · malignant endocrine gland tumour · malignant endocrine neoplasm · malignant endocrine tumor · malignant endocrine tumour · malignant neoplasm of endocrine gland · malignant neoplasm of the endocrine gland · malignant tumor of endocrine gland · malignant tumor of the endocrine gland · malignant tumour of the endocrine gland

Disease family

This is a subtype of endocrine gland neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › malignant endocrine neoplasm

Related subtypes (13): benign endocrine neoplasm, thymus neoplasm, granulosa cell tumor, thyroid tumor, pituitary tumor, familial tumoral calcinosis, neuroendocrine neoplasm, non-functioning endocrine neoplasm, functioning endocrine neoplasm, adrenal gland neoplasm, pineal body neoplasm, tumor of parathyroid gland, liver and intrahepatic bile duct neoplasm

Subtypes (16): thyroid cancer, pituitary cancer, neuroendocrine carcinoma, ovarian neuroendocrine neoplasm, thymus cancer, liver cancer, adrenal gland cancer, pineal gland cancer, malignant carotid body paraganglioma, malignant jugulotympanic paraganglioma, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 5, high-grade neuroendocrine carcinoma of the corpus uteri, low-grade neuroendocrine tumor of the corpus uteri, maligant granulosa cell tumor of ovary, malignant tumor of parathyroid gland

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	2
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01231347	PHASE3	COMPLETED	QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
NCT06416085	PHASE2	ACTIVE_NOT_RECRUITING	Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
NCT00896454	PHASE2	COMPLETED	Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
NCT01552434	PHASE1	TERMINATED	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
NCT03420963	PHASE1	TERMINATED	Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
NCT07121998	Not specified	RECRUITING	Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms
NCT01135849	Not specified	COMPLETED	B-Receptor Signaling in Cardiomyopathy
NCT02583815	Not specified	COMPLETED	Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP)
NCT04035447	Not specified	COMPLETED	Symptom Management for YA Cancer Survivors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GEMCITABINE	4	1
PSILOCYBIN	3	1
MEBUFOTENIN	2	1